- Home
- SUNE vs QNRX Comparison
SUNE vs QNRX Comparison
Compare SUNE & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SUNE
- QNRX
- Stock Information
- Founded
- SUNE 1969
- QNRX 2018
- Country
- SUNE United States
- QNRX United States
- Employees
- SUNE N/A
- QNRX N/A
- Industry
- SUNE
- QNRX Medical/Dental Instruments
- Sector
- SUNE
- QNRX Health Care
- Exchange
- SUNE NYSE
- QNRX Nasdaq
- Market Cap
- SUNE 5.8M
- QNRX 5.5M
- IPO Year
- SUNE N/A
- QNRX N/A
- Fundamental
- Price
- SUNE $1.69
- QNRX $8.89
- Analyst Decision
- SUNE
- QNRX
- Analyst Count
- SUNE 0
- QNRX 0
- Target Price
- SUNE N/A
- QNRX N/A
- AVG Volume (30 Days)
- SUNE 162.3K
- QNRX 7.7K
- Earning Date
- SUNE 08-05-2025
- QNRX 08-07-2025
- Dividend Yield
- SUNE N/A
- QNRX N/A
- EPS Growth
- SUNE N/A
- QNRX N/A
- EPS
- SUNE N/A
- QNRX N/A
- Revenue
- SUNE $56,279,194.00
- QNRX N/A
- Revenue This Year
- SUNE N/A
- QNRX N/A
- Revenue Next Year
- SUNE N/A
- QNRX N/A
- P/E Ratio
- SUNE N/A
- QNRX N/A
- Revenue Growth
- SUNE N/A
- QNRX N/A
- 52 Week Low
- SUNE $1.38
- QNRX $5.01
- 52 Week High
- SUNE $27,400.00
- QNRX $54.95
- Technical
- Relative Strength Index (RSI)
- SUNE N/A
- QNRX 51.38
- Support Level
- SUNE N/A
- QNRX $8.60
- Resistance Level
- SUNE N/A
- QNRX $9.40
- Average True Range (ATR)
- SUNE 0.00
- QNRX 0.50
- MACD
- SUNE 0.00
- QNRX -0.05
- Stochastic Oscillator
- SUNE 0.00
- QNRX 46.11
About SUNE SUNATION ENERGY INC
SUNation Energy Inc provides households with sustainable solar energy, back-up power and security, control and predictability, and cost savings. The company provides a full range of installation services, including design, engineering, procurement, permitting, construction, grid connection, warranty, monitoring, and maintenance of residential solar energy systems. It also offers battery storage to customers in select markets and serves a limited number of enterprise customers.
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.